Market Overview:
The global VEGF targeted drugs for breast cancer market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of breast cancer, technological advancements in the field of oncology, and rising awareness about early diagnosis and treatment options for breast cancer. The global VEGF targeted drugs for breast cancer market is segmented by type into bevacizumab, sorafenib, ramucirumab, sunitinib, and apatinib. By application, the market is segmented into hospitals, clinics Drug centers), and other segments. Geographically, the global VEGF targeted drugs for breast cancer market is segmented into North America (the U.S., Canada), Latin America (Mexico Brazil), Europe (Germany France Italy Spain United Kingdom Rest Of Europe), Asia Pacific (China Japan India South Korea Australia New Zealand Rest Of Asia Pacific) Middle East & Africa (GCC Countries Turkey Nigeria South Africa Rest Of Middle East & Africa).
Product Definition:
VEGF targeted drugs are used to treat breast cancer. This type of drug blocks the action of vascular endothelial growth factor (VEGF), a protein that promotes the growth and spread of cancer cells. By blocking VEGF, these drugs can help slow or stop the growth of tumors.
Bevacizumab:
Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) for the treatment of breast cancer. Bevacizumab was approved by the U.S.
Sorafenib:
Sorafenib is a targeted drug that interferes with the growth of cancer cells. It works by blocking an important blood vessel protein, called vascular endothelial growth factor (VEGF). The main target for sorafenib is the breast tumor cells (mammary carcinoma), which feed off of blood vessels to grow and spread.
Application Insights:
The other application segment held the largest share of over 70.0% in 2017. Other applications include cancer treatment centers, research studies and others. The growing number of clinical trials with bevacizumab for breast cancer is expected to boost its usage in the near future. In addition, sorafenib is used for advanced breast cancers that have become resistant to chemotherapy or radiation therapy; this factor is anticipated to fuel market growth during the forecast period.
Clinical trials are conducted frequently for new drug development and VEGF targeted drugs are no exception; however, they face several challenges due to high cost and complexity associated with them which limit their usage in clinics as compared to hospitals or other settings where these drugs can be administered easily by a healthcare professional without any special training or expertise related specifically towards VEGF targeted therapies for breast cancer treatment at an outpatient basis outside of a clinical trial setting.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of key players, high awareness levels regarding targeted therapy for breast cancer, and availability of highly advanced healthcare infrastructure. Moreover, rising incidence rates coupled with increasing life expectancy are some other factors contributing to the growth of this region.
Asia Pacific is expected to witness lucrative growth over the forecast period due to an increase in awareness about early diagnosis and treatment options along with government support & funding for R&D activities pertaining to cancer research. In addition, economic development in countries such as China & India has led these nations being potential markets for these drugs; thus driving regional market growth. Furthermore, Japan’s regulatory authority approved bevacizumab (Avastin) on March 15th 2018 which will further boost revenue generation from Asia Pacific region during the forecast period.
Growth Factors:
- Increasing incidence of breast cancer
- Rising awareness about VEGF targeted drugs for breast cancer treatment
- Technological advancements in the field of oncology
- Availability of government funding for research and development activities related to VEGF targeted drugs for breast cancer treatment
- Growing number of clinical trials evaluating the efficacy and safety of VEGF targeted drugs for breast cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
VEGF Targeted Drugs for Breast Cancer Market Research Report
By Type
Bevacizumab, Sorafenib, Ramucirumab, Sunitinib, Apatinib
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Genentech, Allergan, Hetero Drugs, Reliance Life Science, Bayer, Natco Pharma, Cipla, Mylan, Eli Lilly, Pfizer, Advenchen Laboratories, Jiangsu Hengrui Medicine, LSK BioPartners, Bukwang Pharmaceutical Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
167
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global VEGF Targeted Drugs for Breast Cancer Market Report Segments:
The global VEGF Targeted Drugs for Breast Cancer market is segmented on the basis of:
Types
Bevacizumab, Sorafenib, Ramucirumab, Sunitinib, Apatinib
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genentech
- Allergan
- Hetero Drugs
- Reliance Life Science
- Bayer
- Natco Pharma
- Cipla
- Mylan
- Eli Lilly
- Pfizer
- Advenchen Laboratories
- Jiangsu Hengrui Medicine
- LSK BioPartners
- Bukwang Pharmaceutical Company
Highlights of The VEGF Targeted Drugs for Breast Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bevacizumab
- Sorafenib
- Ramucirumab
- Sunitinib
- Apatinib
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the VEGF Targeted Drugs for Breast Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
VEGF targeted drugs are medications that block the action of vascular endothelial growth factor (VEGF). This can help to stop the growth of cancer cells in the body. VEGF targeted drugs are often used to treat breast cancer.
Some of the key players operating in the vegf targeted drugs for breast cancer market are Genentech, Allergan, Hetero Drugs, Reliance Life Science, Bayer, Natco Pharma, Cipla, Mylan, Eli Lilly, Pfizer, Advenchen Laboratories, Jiangsu Hengrui Medicine, LSK BioPartners, Bukwang Pharmaceutical Company.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 VEGF Targeted Drugs for Breast Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 VEGF Targeted Drugs for Breast Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 VEGF Targeted Drugs for Breast Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the VEGF Targeted Drugs for Breast Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global VEGF Targeted Drugs for Breast Cancer Market Size & Forecast, 2018-2028
4.5.1 VEGF Targeted Drugs for Breast Cancer Market Size and Y-o-Y Growth
4.5.2 VEGF Targeted Drugs for Breast Cancer Market Absolute $ Opportunity
Chapter 5 Global VEGF Targeted Drugs for Breast Cancer Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Type
5.2.1 Bevacizumab
5.2.2 Sorafenib
5.2.3 Ramucirumab
5.2.4 Sunitinib
5.2.5 Apatinib
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global VEGF Targeted Drugs for Breast Cancer Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global VEGF Targeted Drugs for Breast Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America VEGF Targeted Drugs for Breast Cancer Analysis and Forecast
9.1 Introduction
9.2 North America VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Type
9.6.1 Bevacizumab
9.6.2 Sorafenib
9.6.3 Ramucirumab
9.6.4 Sunitinib
9.6.5 Apatinib
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe VEGF Targeted Drugs for Breast Cancer Analysis and Forecast
10.1 Introduction
10.2 Europe VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Type
10.6.1 Bevacizumab
10.6.2 Sorafenib
10.6.3 Ramucirumab
10.6.4 Sunitinib
10.6.5 Apatinib
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific VEGF Targeted Drugs for Breast Cancer Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Type
11.6.1 Bevacizumab
11.6.2 Sorafenib
11.6.3 Ramucirumab
11.6.4 Sunitinib
11.6.5 Apatinib
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America VEGF Targeted Drugs for Breast Cancer Analysis and Forecast
12.1 Introduction
12.2 Latin America VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Type
12.6.1 Bevacizumab
12.6.2 Sorafenib
12.6.3 Ramucirumab
12.6.4 Sunitinib
12.6.5 Apatinib
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) VEGF Targeted Drugs for Breast Cancer Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Type
13.6.1 Bevacizumab
13.6.2 Sorafenib
13.6.3 Ramucirumab
13.6.4 Sunitinib
13.6.5 Apatinib
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) VEGF Targeted Drugs for Breast Cancer Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 VEGF Targeted Drugs for Breast Cancer Market: Competitive Dashboard
14.2 Global VEGF Targeted Drugs for Breast Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Genentech
14.3.2 Allergan
14.3.3 Hetero Drugs
14.3.4 Reliance Life Science
14.3.5 Bayer
14.3.6 Natco Pharma
14.3.7 Cipla
14.3.8 Mylan
14.3.9 Eli Lilly
14.3.10 Pfizer
14.3.11 Advenchen Laboratories
14.3.12 Jiangsu Hengrui Medicine
14.3.13 LSK BioPartners
14.3.14 Bukwang Pharmaceutical Company
